Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 19

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 19
---
, performance
or events expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements
regarding:

| · | our estimates regarding anticipated operating                
 losses, capital requirements and needs for additional funds; |

| · | our ability to raise additional capital when 
 needed and to continue as a going concern;   |

| · | our ability to manufacture, or otherwise secure                                                                   
 the manufacture of, sufficient amounts of our product candidates for our preclinical studies and clinical trials; |

| · | our clinical development plans, including planned 
 clinical trials;                                  |

| · | our research and development plans; |

| · | our ability to select combinations of phages 
 to formulate our product candidates;         |

| · | our development of bacteriophage-based therapies; |

| · | the potential use of bacteriophages to treat 
 bacterial infections;                        |

| · | the potential future of antibiotic resistance; |

| · | the ability for bacteriophage therapies to disrupt           
 and destroy biofilms and restore sensitivity to antibiotics; |

| · | the potential for bacteriophage technology being                           
 uniquely positioned to address the global threat of antibiotic resistance; |

| · | our planned development strategy, presenting                       
 data to regulatory agencies and defining planned clinical studies; |

| · | the expected timing of additional clinical trials,            
 including Phase 1b/Phase 2 or registrational clinical trials; |

| · | our ability to manufacture and secure sufficient          
 quantities of our product candidates for clinical trials; |

| · | the drug product candidates to be supplied by 
 us for clinical trials;                       |

| · | the safety and efficacy of our product candidates; |

| · | our anticipated regulatory pathways for our product 
 candidates;                                         |

| · | the activities to be performed by specific parties 
 in connection with clinical trials;                |

| · | our ability to successfully complete preclinical                                                                                              
 and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected 
 timeframes or at all;                                                                                                                         |

| · | our pursuit of additional indications; |

| · | the content and timing of submissions to and             
 decisions made by the FDA and other regulatory agencies; |

| · | our ability to leverage the experience of our                                 
 management team and to attract and retain management and other key personnel; |

| · | the capacities and performance of our suppliers,                                                          
 manufacturers, contract research organizations and other third parties over whom we have limited control;